ArticleAmerican journal of translational research2023
DC-CIK combined with chemotherapy on the efficacy, immune function, and life quality in colorectal cancer patients after radical resection.
Article in American journal of translational research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 5 citations in OpenAlex.
- An Exploratory in vitro Study of Cytotoxicity and Cytokine Profiling of Cytokine-Induced Killer (CIK) Cells Against HCT-15 Colorectal Cancer (CRC) Cells.ImmunoTargets and therapy · 2026Article
- Preclinical evaluation of DC-CIK cells as potentially effective immunotherapy model for the treatment of glioblastoma.Scientific reports · 2025Article
- Effects of postoperative treatment with chemotherapy and cellular immunotherapy on patients with colorectal cancer.World journal of gastrointestinal surgery · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the efficacy of combined treatment of dendritic cell-cytokine-induced killer cells (DC-CIK) and chemotherapy on colorectal cancer (CRC) patients who have undergone radical resection, and its effect on immune function and quality of life.
methodsData of 103 CRC patients after radical resection admitted to Xianyang First People's Hospital and Yanan University Affiliated Hospital from March 2018 to March 2020 were retrospectively analyzed. A total of 50 patients treated with XELOX chemotherapy were included in the control group (CG). The remaining 53 patients treated with XELOX chemotherapy combined with DC-CIK were included in the observation group (OG). The therapeutic efficacy, immune function indicators, serum tumor markers before and after the treatment, adverse reactions, 2-year survival rate, and quality of life 6 months after the treatment were observed and compared between the two groups.
resultsThe OG was identified to have a better therapeutic effect than the CG (P<0.05). After the treatment, the OG was assessed with significantly higher levels of IgG, IgA, and IgM than the CG. The CEA, CA724, and CA199 levels in the OG were significantly lower than those in the CG after the treatment (P<0.05). No significant difference was identified regarding the incidence of adverse reactions between the two groups (P>0.05). The quality of life six months after the treatment and the 2-year survival rate in the OG were significantly higher than those in the CG (P<0.05). The logistic regression analysis showed that pathological stage, differentiation, and treatment regimen were independent risk factors for poor prognosis (P<0.05).
conclusionDC-CIK combined with chemotherapy can improve the clinical efficacy, immune function, and long-term survival rate of CRC patients who have undergone radical resection. This combined regimen shows safety and is worthy of promotion in clinical practice.
Indexed as
Identifiers
37193178PMC10182484W4376872343What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.